CN105338997A - 类毒素、组合物和相关的方法 - Google Patents

类毒素、组合物和相关的方法 Download PDF

Info

Publication number
CN105338997A
CN105338997A CN201480021368.4A CN201480021368A CN105338997A CN 105338997 A CN105338997 A CN 105338997A CN 201480021368 A CN201480021368 A CN 201480021368A CN 105338997 A CN105338997 A CN 105338997A
Authority
CN
China
Prior art keywords
toxoid
toxin
formaldehyde
composition
clostridium difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480021368.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.豪泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN105338997A publication Critical patent/CN105338997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480021368.4A 2013-03-15 2014-03-14 类毒素、组合物和相关的方法 Pending CN105338997A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
CN105338997A true CN105338997A (zh) 2016-02-17

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480021368.4A Pending CN105338997A (zh) 2013-03-15 2014-03-14 类毒素、组合物和相关的方法

Country Status (13)

Country Link
US (2) US20160045586A1 (enExample)
EP (1) EP2968507A2 (enExample)
JP (1) JP2016516721A (enExample)
KR (1) KR20150133770A (enExample)
CN (1) CN105338997A (enExample)
AR (1) AR095669A1 (enExample)
AU (1) AU2014228956A1 (enExample)
BR (1) BR112015023332A2 (enExample)
CA (1) CA2907154A1 (enExample)
HK (1) HK1213800A1 (enExample)
SG (1) SG11201507608PA (enExample)
TW (1) TWI624474B (enExample)
WO (1) WO2014144567A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611942A (zh) * 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
AU2022408126A1 (en) * 2021-12-06 2024-07-04 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2005058353A1 (en) * 2003-12-16 2005-06-30 Acambis Inc. Passive immunization against clostridium difficile disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
AU2008280755B9 (en) 2007-07-26 2014-09-25 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2005058353A1 (en) * 2003-12-16 2005-06-30 Acambis Inc. Passive immunization against clostridium difficile disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LORNA E.LANCASTER ET AL.,: "An assessment of thermal stability of clostridium difficile toxoid fourmulations", 《HUMAN VACCINES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611942A (zh) * 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法

Also Published As

Publication number Publication date
SG11201507608PA (en) 2015-10-29
WO2014144567A2 (en) 2014-09-18
AR095669A1 (es) 2015-11-04
CA2907154A1 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
EP2968507A2 (en) 2016-01-20
HK1213800A1 (zh) 2016-07-15
AU2014228956A1 (en) 2015-10-08
BR112015023332A2 (pt) 2017-08-22
KR20150133770A (ko) 2015-11-30
TWI624474B (zh) 2018-05-21
JP2016516721A (ja) 2016-06-09
US20180028637A1 (en) 2018-02-01
US20160045586A1 (en) 2016-02-18
WO2014144567A3 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
CN105338997A (zh) 类毒素、组合物和相关的方法
SK283565B6 (sk) Multivalentná imunogénna kompozícia a jej použitie
Alves et al. Clostridium septicum: A review in the light of alpha-toxin and development of vaccines
KR20130067483A (ko) 인간 백신 용도로 적합한 디프테리아 톡소이드 생산을 위한 동물 유래 성분을 함유하지 않는 발효 배지
CN102238960B (zh) 制造疫苗的方法
AU2018204879A1 (en) Toxoid, compositions and related methods
JP2015528457A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
JP3035712B2 (ja) 新規なワクチンおよびそのための方法
JP2016519671A5 (enExample)
US20180110849A1 (en) Methods for immunizing against clostridium difficile
JP7349366B2 (ja) クロストリジウム類毒素を含むワクチン
JP3535436B2 (ja) エリシペロスリクス・ルシオパシエ抗原及びワクチン組成物
JP2015532594A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
EP0563288B1 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
Kumar et al. Immunological studies on a modified water-in-oil-in-water (w/o/w) haemmorhagic septicemia vaccine incorporated with Pasteurella multocida A: 1 in the external aqueous phase
RU2699035C2 (ru) Поливалентная вакцина против анаэробной энтеротоксемии молодняка крупного рогатого скота и способ ее применения
HK1029062B (en) Erysipelothrix rhusiopathiae antigens and vaccine compositions
JPH02101023A (ja) オーエスキー病のサブユニットワクチン、及び製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160217